This comprehensive cancer center group will be composed of highly trained professionals. The goal will be to discuss ideas and describe experiences that others can learn from. These professionals must work together to ultimately create; patient-focused care, custom patient experience and seamless patient flow thru their institution. Objectives; • Group practice as the optimal framework and inf

In a response to issues raised by the COSA membership around complementary medicines COSA has established a Complementary and Integrative Therapies (CIT) interest group with expertise from a range of different areas, as well as...

BACKGROUND Patients with non-Hodgkin’s lymphoma can present with complex clinical scenarios and a variety of clinical features including indolent disease, standard disease, and disease with aggressive phenotypes. This interview...

Despite the presence of numerous excellent development focused group I saw an absence of hard nosed commercial groups specifically designed to focus on the financial aspects of drug development. Drug development is hugely expensive and business and scientific drivers have to be considered. Facilitating partnering and networking to help drive progress in cancer vaccine development.

Targeting c-MET in Lung Cancer. Edgardo S. Santos, M.D., FACP The role of Met in cancer was first noted in 1984 when it was cloned as a fusion oncogene from a human osteosarcoma cell line. Met pathway is amplified, mutated,...